 Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company, today announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. This follows the U.S. Food and Drug Administrations FDA review and acceptance of the Companys investigational new drug IND application for the COVID-19 study. Corvus is studying an agonistic immunostimulatory humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer. 